Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tisotumab vedotin
- Development stage
- Approved
- Lead developer
- Genmab
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Tisotumab vedotin is an antibody-drug conjugate (ADC) used to treat recurrent or metastatic cervical cancer. It consists of a human monoclonal antibody targeting tissue factor (TF) conjugated via a protease-cleavable linker to monomethyl auristatin E (MMAE), a potent microtubule-disrupting agent. The drug binds to TF, which is overexpressed on many solid tumors, leading to internalization and release of MMAE inside the cancer cell, causing cell cycle arrest and apoptosis. Tisotumab vedotin may also block TF’s interaction with factor VIIa, potentially inhibiting angiogenesis and tumor proliferation, and can induce bystander killing of neighboring cells. It was developed as a targeted therapy for cancers expressing high levels of tissue factor.
- Brand names
- Tivdak
- Other names
- tisotumab vedotin-tftv
02
Targets
F3 (Tissue factor)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on tisotumab vedotin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tisotumab vedotin.